SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Down 52.0% in September

SOPHiA GENETICS SA (NASDAQ:SOPH) was the target of a significant decline in short interest in September. As of September 15th, there was short interest totalling 18,900 shares, a decline of 52.0% from the August 31st total of 39,400 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 61,900 shares, the days-to-cover ratio is presently 0.3 days.

SOPHiA GENETICS Trading Down 2.6 %

SOPH traded down $0.10 during trading on Friday, hitting $3.73. 6,733 shares of the company’s stock were exchanged, compared to its average volume of 74,447. The stock has a 50 day moving average price of $3.91 and a 200 day moving average price of $4.50. SOPHiA GENETICS has a 1 year low of $2.41 and a 1 year high of $7.37. The company has a current ratio of 4.40, a quick ratio of 4.17 and a debt-to-equity ratio of 0.11. The firm has a market cap of $243.87 million, a P/E ratio of -3.33 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.05. SOPHiA GENETICS had a negative net margin of 102.84% and a negative return on equity of 47.40%. The company had revenue of $15.81 million for the quarter, compared to analyst estimates of $17.58 million. During the same quarter last year, the firm posted ($0.33) earnings per share. As a group, analysts expect that SOPHiA GENETICS will post -0.95 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Guggenheim assumed coverage on SOPHiA GENETICS in a research note on Thursday, June 27th. They set a “buy” rating and a $6.00 price objective on the stock. Morgan Stanley cut shares of SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $10.00 to $5.00 in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada lowered their target price on shares of SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th.

Institutional Investors Weigh In On SOPHiA GENETICS

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SOPH. Principal Financial Group Inc. raised its position in shares of SOPHiA GENETICS by 35.9% during the second quarter. Principal Financial Group Inc. now owns 1,368,378 shares of the company’s stock worth $6,267,000 after purchasing an additional 361,201 shares during the period. Akre Capital Management LLC acquired a new position in shares of SOPHiA GENETICS during the 1st quarter worth about $1,418,000. Essex Investment Management Co. LLC lifted its stake in shares of SOPHiA GENETICS by 112.1% in the first quarter. Essex Investment Management Co. LLC now owns 262,834 shares of the company’s stock valued at $1,296,000 after buying an additional 138,933 shares during the period. Edmond DE Rothschild Holding S.A. boosted its stake in SOPHiA GENETICS by 5.0% in the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 203,334 shares of the company’s stock valued at $1,002,000 after buying an additional 9,700 shares in the last quarter. Finally, Moloney Securities Asset Management LLC raised its position in SOPHiA GENETICS by 111.4% in the 1st quarter. Moloney Securities Asset Management LLC now owns 178,000 shares of the company’s stock valued at $878,000 after purchasing an additional 93,800 shares during the last quarter. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.